Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity.
ACS Med Chem Lett
; 1(9): 493-8, 2010 Dec 09.
Article
en En
| MEDLINE
| ID: mdl-24900237
ABSTRACT
A series of novel 7-amino-1,3,4,5-tetrahydrobenzo[b]azepin-2-one derivatives within the diaminopyrimidine class of kinase inhibitors were identified that target anaplastic lymphoma kinase (ALK). These inhibitors are potent against ALK in an isolated enzyme assay and inhibit autophosphorylation of the oncogenic fusion protein NPM-ALK in anaplastic large cell lymphoma (ALCL) cell lines. The lead inhibitor 15, which incorporates a bicyclo[2.2.1]hept-5-ene ring system in place of an aryl moiety, activates the pro-apoptotic caspases (3 and 7) and displays selective cytotoxicity against ALK-positive ALCL cells. Furthermore, 15 provides more than 40-fold selectivity against the structurally related insulin receptor, is orally bioavailable in multiple species, and displays in vivo antitumor efficacy when dosed orally in ALK-positive ALCL tumor xenografts in Scid mice.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
ACS Med Chem Lett
Año:
2010
Tipo del documento:
Article